Luteal Phase Support in Insemination Cycles
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03115307|
Recruitment Status : Recruiting
First Posted : April 14, 2017
Last Update Posted : April 26, 2018
|Condition or disease||Intervention/treatment||Phase|
|Infertility, Female||Drug: Triptorelin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||242 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Protocol for a Randomized, Controlled Study to Compare the Use of Gonodotropin-releasing Hormone Agonist Triptoreline (Gonapeptyl®) for Luteal Phase Support Versus Natural Luteal Phase in the Insemination Cycles|
|Actual Study Start Date :||January 2017|
|Estimated Primary Completion Date :||December 2021|
|Estimated Study Completion Date :||December 2021|
In the intervention group the patient will get the advice to using triptoreline (Gonapeptyl®) in the eight day after the injection of hCG (Pregnyl®) in the insemination cycle.
Triptoreline 0,1mg/ml subcutaneously once in a luteal phase in insemination cycles.
No Intervention: Control group
In the control group, there are no luteal phase medications in the insemination cycle.
- Live birth rate [ Time Frame: At possible delivery (about 40 weeks) ]
- Ongoing pregnancy rate [ Time Frame: After two weeks ]
- Miscarriage rate [ Time Frame: During subsequent about 40 weeks of pregnancy ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03115307
|Tampere University Hospital||Recruiting|
|Contact: Helena Tinkanen, M.D., Ph.D.|
|Contact: Riikka Leppänen, M.D.|
|Principal Investigator:||Helena Tinkanen||Tampere University Hospital|